Enzalutamide + Abiraterone acetate

Pre-clinicalCompleted
0 watching 0 views this week๐Ÿ’ค Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Prostatic Neoplasms, Castration-Resistant

Conditions

Prostatic Neoplasms, Castration-Resistant

Trial Timeline

Jul 24, 2023 โ†’ Feb 14, 2025

About Enzalutamide + Abiraterone acetate

Enzalutamide + Abiraterone acetate is a pre-clinical stage product being developed by Astellas Pharma for Prostatic Neoplasms, Castration-Resistant. The current trial status is completed. This product is registered under clinical trial identifier NCT05968599. Target conditions include Prostatic Neoplasms, Castration-Resistant.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT05968599Pre-clinicalCompleted

Competing Products

20 competing products in Prostatic Neoplasms, Castration-Resistant

See all competitors